DOP2013000311A - Cristal de compuesto heterocíclico fusionado - Google Patents

Cristal de compuesto heterocíclico fusionado

Info

Publication number
DOP2013000311A
DOP2013000311A DO2013000311A DO2013000311A DOP2013000311A DO P2013000311 A DOP2013000311 A DO P2013000311A DO 2013000311 A DO2013000311 A DO 2013000311A DO 2013000311 A DO2013000311 A DO 2013000311A DO P2013000311 A DOP2013000311 A DO P2013000311A
Authority
DO
Dominican Republic
Prior art keywords
fused heterocyclic
composite crystal
imidazo
pyridin
methyl
Prior art date
Application number
DO2013000311A
Other languages
English (en)
Inventor
Katsuhiko Yamamoto
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of DOP2013000311A publication Critical patent/DOP2013000311A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente invención se refiere a un cristal de 1-etil-7-metil-3-{4-[(3- metil-3H-imidazo[4,5-b]piridin-2-il)oxi]fenil}-1,3-dihidro-2H-imidazo[4,5-b]piridin-2- ona útil como un agente profiláctico o terapéutico para la esquizofrenia y similares, que muestra un patrón de difracción de polvo por rayos X con picos característicos en espaciamientos interplanares (d) de 13,59±0,2 y 6,76±0,2 Angstroms en la difracción de polvo por rayos X.
DO2013000311A 2011-06-22 2013-12-20 Cristal de compuesto heterocíclico fusionado DOP2013000311A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2011138920 2011-06-22

Publications (1)

Publication Number Publication Date
DOP2013000311A true DOP2013000311A (es) 2014-02-28

Family

ID=46551819

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2013000311A DOP2013000311A (es) 2011-06-22 2013-12-20 Cristal de compuesto heterocíclico fusionado

Country Status (26)

Country Link
US (1) US9512118B2 (es)
EP (1) EP2723738B1 (es)
JP (1) JP6025757B2 (es)
KR (1) KR20140040777A (es)
CN (1) CN103608348B (es)
AR (1) AR087004A1 (es)
AU (1) AU2012274292B2 (es)
BR (1) BR112013032052A2 (es)
CA (1) CA2839825C (es)
CL (1) CL2013003632A1 (es)
CO (1) CO6862150A2 (es)
CR (1) CR20140033A (es)
DO (1) DOP2013000311A (es)
EA (1) EA026137B1 (es)
EC (1) ECSP14013165A (es)
GE (1) GEP20166475B (es)
MA (1) MA35274B1 (es)
MX (1) MX342990B (es)
MY (1) MY163483A (es)
PE (1) PE20141030A1 (es)
TN (1) TN2013000510A1 (es)
TW (1) TWI570122B (es)
UA (1) UA112082C2 (es)
UY (1) UY34150A (es)
WO (1) WO2012176934A1 (es)
ZA (1) ZA201309611B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012124782A1 (ja) * 2011-03-16 2012-09-20 武田薬品工業株式会社 縮合複素環化合物
US10308626B1 (en) 2018-07-02 2019-06-04 Pratt Bethers Crystal purification in a glass or metal container
US10960322B2 (en) 2018-07-02 2021-03-30 Pratt Bethers Apparatus for purifying crystals using solvent vapors
US10851076B2 (en) 2017-08-10 2020-12-01 Pratt Bethers Method for purifying crystals using solvent vapors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597826A (en) * 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
WO2006038111A1 (en) * 2004-10-07 2006-04-13 Pfizer Products Inc. Benzoimidazole derivatives useful as antiproliferative agents
JP5220414B2 (ja) 2005-08-30 2013-06-26 旭化成ファーマ株式会社 スルホンアミド化合物
FI20055498A0 (fi) 2005-09-16 2005-09-16 Biotie Therapies Corp Sulfonamidijohdannaisia
US7618982B2 (en) 2005-12-19 2009-11-17 Nerviano Medical Sciences S.R.L. Heteroarylpyrrolopyridinones active as kinase inhibitors
JP5175228B2 (ja) * 2006-02-15 2013-04-03 サノフイ 新規なアザシクリル置換アリールジヒドロイソキノリノン、それらの製造方法及び薬剤としてそれらの使用
US20080090834A1 (en) 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
KR101524817B1 (ko) 2007-04-18 2015-06-01 깃세이 야쿠힌 고교 가부시키가이샤 질소 함유 축합환 유도체, 그것을 함유하는 의약 조성물 및 그 의약 용도
US20110098288A1 (en) 2008-03-11 2011-04-28 Jeremy Major Sulfonamides as zap-70 inhibitors
AR074343A1 (es) 2008-11-14 2011-01-12 Amgen Inc Derivados de piridina y pirimidina como inhibidores de la fosfodiesterasa 10
TWI396689B (zh) 2008-11-14 2013-05-21 Amgen Inc 作為磷酸二酯酶10抑制劑之吡衍生物
WO2010126002A1 (ja) 2009-04-28 2010-11-04 塩野義製薬株式会社 ヘテロ環スルホンアミド化合物を含有する医薬
BR112012032087A2 (pt) * 2010-06-24 2016-11-16 Takeda Pharmaceuticals Co composto, medicamento, e, uso de um composto
EP2601192B1 (en) 2010-08-04 2017-03-01 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
EP2604597B1 (en) 2010-08-10 2017-01-04 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof inhibitor of phosphodiesterase 10a
WO2012124782A1 (ja) 2011-03-16 2012-09-20 武田薬品工業株式会社 縮合複素環化合物

Also Published As

Publication number Publication date
GEP20166475B (en) 2016-05-10
EP2723738A1 (en) 2014-04-30
TW201313709A (zh) 2013-04-01
CN103608348A (zh) 2014-02-26
CR20140033A (es) 2014-03-12
UY34150A (es) 2013-01-31
AR087004A1 (es) 2014-02-05
CL2013003632A1 (es) 2014-06-06
ECSP14013165A (es) 2014-02-28
EP2723738B1 (en) 2018-03-14
ZA201309611B (en) 2014-08-27
JP6025757B2 (ja) 2016-11-16
TN2013000510A1 (en) 2015-03-30
WO2012176934A1 (en) 2012-12-27
CN103608348B (zh) 2016-03-30
MX342990B (es) 2016-10-20
EA201490092A1 (ru) 2014-05-30
KR20140040777A (ko) 2014-04-03
AU2012274292A1 (en) 2014-01-16
MX2013015354A (es) 2014-02-11
PE20141030A1 (es) 2014-08-29
EA026137B1 (ru) 2017-03-31
NZ618944A (en) 2015-08-28
TWI570122B (zh) 2017-02-11
UA112082C2 (uk) 2016-07-25
JP2014516918A (ja) 2014-07-17
US20140113932A1 (en) 2014-04-24
US9512118B2 (en) 2016-12-06
CA2839825A1 (en) 2012-12-27
MY163483A (en) 2017-09-15
AU2012274292B2 (en) 2016-10-27
CA2839825C (en) 2019-04-09
CO6862150A2 (es) 2014-02-10
MA35274B1 (fr) 2014-07-03
BR112013032052A2 (pt) 2016-12-13

Similar Documents

Publication Publication Date Title
HRP20182007T1 (hr) Derivati 3-okso-2,3,5,8-tetrahidro-[1,2,4]triazolo[4,3-a]pirimidina za liječenje respiratornih bolesti
PH12015500988B1 (en) Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
IL229193A0 (en) The history of pyridine-2--(h1) and its effectiveness as drugs for the treatment of myeloproliferative disorders, graft rejection, and infectious and immune-mediated diseases
BR112014032338A2 (pt) cristais de sal
ECSP14013165A (es) Cristal de compuesto heterocíclico fusionado
AP3908A (en) Novel 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo [4,5-B] pyridine compounds as modulators of C-met protein kinases
ZA201208894B (en) Process for the preparation of 5-substituted-8-alkoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-amines
ZA201500865B (en) Process for the preparation of sitagliptin and intermediate compounds
IL226054A0 (en) Oxazolo[4,5-b]pyridin-5-yl compounds and their use in cancer treatment
EP2480229A4 (en) ZINC-BASED COMPOSITIONS FOR THE TREATMENT OF DISORDERS, DISEASES AND SYNDROMES ASSOCIATED WITH EXPOSURE TO POROUS FORMING TOXINS
IL236480B (en) A process for the preparation of n-oxides of 5-(1-alkylthio)alkyl-pyridine substituted in position 2
PL393991A1 (pl) Sposób wytwarzania kompozytowego katalizatora do niskotemperaturowego rozkładu podtlenku azotu
SG10201600776VA (en) Method of miniature two axes four-wheel drive control with precision magnetic encoder design
SG2012080370A (en) Method of miniature two axes four-wheel drive control with precision magnetic encoder design
TN2013000231A1 (en) Oxazolo [5, 4 -b] pyridin- 5 -yl compounds and their use for the treatment of cancer
CU24344B1 (es) Imidazo[1,2-a]piridincarboxamidas aminosustituidas
UA72222U (ru) Способ лечения геликобактер-ассоциированной язвенной болезни у детей
NZ623063A (en) Antibacterial compounds and methods for use